

Match Overview

1	Internet 27 words crawled on 22-Nov-2018 www.esmo.org	<1%
2	Internet 24 words crawled on 09-Dec-2019 jeccr.biomedcentral.com	<1%
3	Internet 22 words crawled on 01-Mar-2020 journals.sagepub.com	<1%
4	Internet 22 words crawled on 07-Oct-2018 www.skincancer.org	<1%
5	Internet 19 words crawled on 05-Mar-2020 www.cancerhealth.com	<1%
6	Internet 18 words crawled on 27-Feb-2020 jitc.biomedcentral.com	<1%
7	Internet 16 words crawled on 25-Jun-2019 hbsn.amegroups.com	<1%
8	Internet 16 words crawled on 03-May-2020	<1%

14

Name of Journal: *World Journal of Meta-Analysis***Manuscript NO:** 54481**Manuscript Type:** REVIEW**Immunotherapy in hepatocellular carcinoma:** Combination strategies

Alexander Claudius Jordan, Jennifer Wu

Abstract

Liver cancer is one of the most common causes of cancer death globally, and its incidence in the United States is increasing. Patients with advanced hepatocellular carcinoma (HCC) who are not candidates for surgical resection, liver transplant, or locoregional therapies can be treated with systemic therapies. Multiple agents, including sorafenib, lenvatinib, and regorafenib are approved for use as either first- or second-line therapy in this patient population, but all have relatively modest survival benefits. HCC is potentially susceptible to therapy with checkpoint inhibitors, including agents such as

国内版

国际版

Immunotherapy in hepatocellular carcinoma: Combinatic



ALL

IMAGES

VIDEOS

725,000 Results

Any time ▾

[Combination Cancer Immunotherapy in Hepatocellular ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892358>

Jan 31, 2018 · Combination cancer immunotherapy is becoming a major topic in **cancer therapy** research including in **hepatocellular carcinoma** (HCC). Well-known combinations include two types of immune checkpoint inhibitors (anti-PD-1/PD-L1 and anti-CTLA-4 antibodies), anti-PD-1/PD-L1 antibody with a molecular targeted agent, and anti-PD-1/PD-L1 or -CTLA-4 antibody with existing locoregional ...

Cited by: 7

Author: Masatoshi Kudo

Publish Year: 2018

[Immunotherapy in hepatocellular carcinoma - ScienceDirect](#)

<https://www.sciencedirect.com/science/article/pii/S1665268119300377>

Active **immunotherapy** approaches: **cancer vaccine strategies** Similar to ICIs clinical trials, also the number of **cancer vaccine** clinical trials in **HCC** are very limited showing only some degree of efficacy.

Cited by: 5

Author: Luigi Buonaguro, Angela Mauriello, Beatri...

Publish Year: 2019

[Combinatorial immunotherapy strategies for hepatocellular ...](#)

<https://www.sciencedirect.com/science/article/pii/S0952791516000170>

Hepatocellular carcinoma (HCC) is the most common **liver malignancy**. The **prognosis** for **HCC patients** greatly varies according to the stage at diagnosis. Overall it is poor, with a 5-year survival rate of approximately 5–6%. **Immunotherapeutic interventions** represent a novel and effective therapeutic tool.

Cited by: 27

Author: Maria Tagliamonte, Annacarmen Petruzzo...

Publish Year: 2016

Related

treatment o

hepatocellu

screening f

hepatocellu

hepatocellu

hepatocellu

death signs

stage 4 hep

Search T

Turn off How



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

715,000 Results

Any time ▾

Combination Cancer Immunotherapy in Hepatocellular Carcinoma

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892358>

Jan 31, 2018 · Combination cancer immunotherapy is becoming a major topic in **cancer therapy** research including in **hepatocellular carcinoma** (HCC). Well-known combinations include two types of immune checkpoint inhibitors (anti-PD-1/PD-L1 and anti-CTLA-4 antibodies), anti-PD-1/PD-L1 antibody with a molecular targeted agent, and anti-PD-1/PD-L1 or -CTLA-4 antibody with existing locoregional ...

Cited by: 7

Author: Masatoshi Kudo

Publish Year: 2018

Combinatorial immunotherapy strategies for hepatocellular ...

<https://www.sciencedirect.com/science/article/pii/S0952791516000170>

Immunotherapy approaches for HCC A limited number of **immunotherapy trials** for HCC have been conducted based on several **strategies**, with yet modest results. They are based on cellular and **non-cellular strategies**, which may be further divided into active and passive **immunotherapy strategies**.

Cited by: 27

Author: Maria Tagliamonte, Annacarmen Petrizzo, ...

Publish Year: 2016

Immunotherapy of hepatocellular carcinoma: strategies for ...

<https://www.ncbi.nlm.nih.gov/pubmed/31119560>

immunotherapy trials have been conducted in HCC patients, and there is an unmet need for novel **therapeutic strategies**. The **combination** of **conventional treatments** with specific **immunotherapeutic** approaches may dramatically improve the efficacy of HCC treatment and the clinical outcome of HCC patients. In this review, we

Cited by: 3


Author: Mengxin Tian, Yinghong Shi, Weiren Liu, ...

Publish Year: 2019

Immunotherapy of hepatocellular carcinoma: strategies for ...

Hepatocellular Carcinoma

Medical Condition



The most common form of liver cancer often seen in people with chronic liver diseases like cirrhosis.

🏠 Rare (Fewer than 200,000 cases per year in US)

📌 May be preventable by vaccine

🧪 Often requires lab test or imaging

👨🏻‍⚕️ Treatment from medical professional advised

🕒 Can last several months or years

Caused mainly due to the chronic infection of the liver or DNA mutation of the liver cells. Characterized by unexplained weight loss, upper abdominal pain and yellowing of the skin. Treatment options include hepatectomy